Blockchain Registration Transaction Record

Quantum BioPharma Targets MS with Novel Myelin Repair Drug

Quantum BioPharma (NASDAQ: QNTM) announces novel myelin repair drug Lucid-MS for multiple sclerosis in NetworkNewsAudio. Learn about its potential to reverse MS progression and address a $38.62B market.

This news matters because multiple sclerosis affects millions worldwide, and current treatments primarily manage symptoms rather than addressing the underlying cause—myelin degradation. Quantum BioPharma's Lucid-MS, a first-in-class candidate that targets myelin repair, could potentially halt or reverse disease progression, offering new hope for patients. If successful, this therapy could significantly improve quality of life and reduce long-term disability, transforming the MS treatment landscape and addressing a massive unmet need in a market projected to reach $38.62 billion by 2030.